CRC Research Update — October 05, 2026
Today's colorectal cancer research highlights
Curated CRC research, accessible, accurate, actionable
The CRC Digest
Monday, October 05, 2026
IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.
CRC Research Update
-
TRIAL DATA
Phase II trial compares sequencing of regorafenib and anti-EGFR therapy in refractory metastatic colorectal cancerThe REVERCE II trial randomized patients with RAS wild-type metastatic colorectal cancer to receive either regorafenib followed by anti-EGFR therapy or the reverse sequence, evaluating overall survival as the primary endpoint. (The Oncologist)
-
RESEARCH
SPP1+ macrophages linked to chemotherapy resistance in colorectal liver metastasisSingle-cell RNA sequencing identified a macrophage subpopulation marked by elevated SPP1 expression that is significantly enriched in patients who respond insufficiently to neoadjuvant chemotherapy; these cells suppress CD8+ T cell function through the SPP1-CD44 signaling pathway. (Molecular Biomedicine)
-
TREATMENT
Real-world data show fruquintinib efficacy in Japanese patients with advanced colorectal cancerA multicentre retrospective study of 171 Japanese patients with unresectable or recurrent colorectal cancer treated with fruquintinib monotherapy evaluated real-world progression-free survival, overall survival, and safety outcomes. (ESMO Gastrointestinal Oncology)
-
RESEARCH
Hybrid-capture sequencing platform enhances ctDNA minimal residual disease detectionA novel hybrid capture-based sequencing workflow combined with genome-wide features including copy number alterations, fragmentomics, and end-motif signatures was validated using reference standards, plasma samples of cancer patients, and healthy donors for tumor-informed and tumor-naïve liquid biopsy profiling. (Journal of Liquid Biopsy)
-
RESEARCH
Meta-analysis evaluates ctDNA-guided adjuvant chemotherapy in resectable colorectal cancerA systematic review of cohort studies from January 2010 to July 2026 assessed the efficacy of circulating tumor DNA-guided adjuvant chemotherapy in patients with resectable colorectal cancer, reporting recurrence-free survival and overall survival outcomes. (Oncology Letters)
Today's research spans treatment sequencing strategies, mechanisms of chemotherapy resistance, and advances in liquid biopsy technology for minimal residual disease detection.
Get CRC research intelligence delivered weekly, free.
SubscribeCRC Digest
Not Medical Advice
The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.
Content is curated with AI assistance and reviewed by the editorial team.
Browse Past Issues · Read our full disclaimer · Manage subscription
Useful? Forward it to a colleague. Many of the topics named here have a live research dossier, trajectory and evidence, at Signal Bureau.
Got this from a colleague? Subscribe here. We only ever add readers who sign themselves up.
Evolution Accelerator, Inc. (dba Evolution Labs) · 3941 Park Dr., Suite 20341, El Dorado Hills, CA 95762
You are receiving this because you subscribed to CRC Digest (self-serve signup)
Unsubscribe: honored promptly, no login required. · Privacy policy · Manage or delete your data